Bioactive FGF-2 in sterilized extracellular matrix

被引:0
|
作者
Hodde, JP [1 ]
Hiles, MC [1 ]
机构
[1] Cook Biotech Incorp, W Lafayette, IN 47906 USA
来源
WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE | 2001年 / 13卷 / 05期
关键词
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Retention of growth factor activity during disinfection, lyophilization, and sterilization may be key to the development of safe, yet effective, human clinical products derived from biological sources. Traditional methods to reduce the antigenicity of biological materials used for wound healing are thought to destroy the bioactivity of growth factors contained within naturally occurring extracellular matrices. A sterilized extracellular matrix wound dressing (sECM) was examined for bioactive FGF-2 using a sandwich ELISA and an in-vitro bioassay. FGF-2 was present in sECM at a concentration as great as 97.9 +/- 11.7 ng/g. To detect bioactivity, the cell culture medium was incubated with sECM (sECM-CM) and was used as the growth medium for rat pheochromocytoma (PC12) cells. After 48 hours, sECM-CM induced differentiation in 22 percent of the cells versus eight percent of the positive controls. Addition of an FGF-2 neutralizing antibody reduced PC12 differentiation in the sECM-CM-treated cells to nine percent versus one percent in the control wells. These results indicate that both the presence and the bioactivity of FGF-2 are retained in sECM. Because FGF-2 is an important regulator of angiogenesis, wound healing, and regeneration, it is likely that bioactive FGF-2 retained in sECM contributes to the clinical successes observed when this material is used to treat hard-to-heal wounds.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 50 条
  • [31] FGF-2 in vascular development in the avian embryo
    Cox, CM
    Poole, TJ
    FASEB JOURNAL, 2001, 15 (05): : A741 - A741
  • [32] Role of FGF-2/FGFR in choroidal melanomas
    Mouriaux, F
    Lefevre, G
    Calipel, A
    Malecaze, F
    Courtois, Y
    Mascarelli, F
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 : U515 - U515
  • [33] REGULATION OF BONE FORMATION BY THE FGF-2 PATHWAY
    Hurley, M. M.
    CALCIFIED TISSUE INTERNATIONAL, 2004, 74 : S22 - S22
  • [34] Translokin is an intracellular mediator of FGF-2 trafficking
    Bossard, C
    Laurell, H
    Van den Berghe, L
    Meunier, S
    Zanibellato, C
    Prats, H
    NATURE CELL BIOLOGY, 2003, 5 (05) : 433 - 439
  • [35] FGF-2 is bound to perlecan in the pericellular matrix of articular cartilage, where it acts as a chondrocyte mechanotransducer
    Vincent, T. L.
    McLean, C. J.
    Full, L. E.
    Peston, D.
    Saklatvala, J.
    OSTEOARTHRITIS AND CARTILAGE, 2007, 15 (07) : 752 - 763
  • [36] FGF-2: five star translation.
    Prats, AC
    Prats, H
    M S-MEDECINE SCIENCES, 1999, 15 (6-7): : 905 - 906
  • [37] Delivery of exogenous DNA into the nucleus by FGF-2
    He, DC
    Willerson, JT
    Casscells, W
    Engler, DA
    FASEB JOURNAL, 2000, 14 (04): : A278 - A278
  • [38] Low concentrations of extracellular FGF-2 are sufficient but not essential for neurogenesis from human neural progenitor cells
    Nelson, Aaron D.
    Svendsen, Clive N.
    MOLECULAR AND CELLULAR NEUROSCIENCE, 2006, 33 (01) : 29 - 35
  • [39] Regulation of FGF-2 export by cardenolides.
    Florkiewicz, RZ
    Anchin, J
    Trudel, C
    Baird, A
    MOLECULAR BIOLOGY OF THE CELL, 1996, 7 : 1080 - 1080
  • [40] FGF-2 for subacute tympanic membrane perforations
    Lou, Zhengcai
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 2017, 38 (01) : 113 - 114